Classement en actions
#37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
Prix de l'action
$0.051239
Dernière synchronisation: 2025-11-24
Capitalisation boursière
$1.38M
Changement (1 jour)
-4.48%
Changement (1 an)
-54.57%
Échange BerGenBio ASA (BGBIO)
Le prix BGBIO avec la capitalisation boursière de B
Capitalisation boursière de BerGenBio ASA(BGBIO)
Capitalisation boursière: $1.38M
En August 2026, BerGenBio ASA a une capitalisation boursière de $1.38M. Cela fait de BerGenBio ASA la 37880th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de BerGenBio ASA du 2017 au 2026
BGBIO par rapport au top 5 des plus populaires stocks
| Prix pour BGBIO |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.452T
|
+395,719,658.51%
|
|
|
|
|
$4.490T
|
+325,904,669.51%
|
|
|
|
|
$4.162T
|
+302,125,113.01%
|
|
|
|
|
$3.676T
|
+266,844,477.57%
|
|
|
|
|
$2.833T
|
+205,634,188.75%
|
